人工智能驱动的多发性硬化进展重新分类
四个维度定义疾病状态:身体残疾、脑损伤、复发和亚临床疾病活动。早期/轻度/演变型与晚期多发性硬化构成疾病严重程度谱的两极,结果在独立临床试验数据库和真实世界队列(合计逾4000例)中得到验证。
要点
- 多发性硬化疾病状态由身体残疾、脑损伤、复发和亚临床疾病活动四个维度定义。
- 早期/轻度/演变型与晚期多发性硬化构成疾病严重程度谱的两极。
- 晚期多发性硬化以中度至高度残疾、影像学疾病负担和独立于复发的进展风险为特征。
核心结论
- 研究结果支持将多发性硬化视为一个疾病连续谱。
- 作者提出简化的疾病分类,以统一对该疾病的理解、改善患者管理并提高药物研发效率与精准性。
研究设计与样本
- 结果在独立临床试验数据库和真实世界队列(合计逾4000例多发性硬化患者)中得到验证。
主要发现
- 四个维度定义多发性硬化疾病状态:身体残疾、脑损伤、复发和亚临床疾病活动。
- 早期/轻度/演变型多发性硬化患者临床损害有限、脑损伤轻微。
- 向晚期多发性硬化的转变通过炎症状态下的脑损伤累积发生,可伴有或不伴有症状。
- 晚期多发性硬化以中度至高度残疾、影像学疾病负担和独立于复发的疾病进展风险为特征,恢复到较早多发性硬化状态的概率很小。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Multiple sclerosis (MS) affects 2.9 million people. Traditional classification of MS into distinct subtypes poorly reflects its pathobiology and has limited value for prognosticating disease evolution and treatment response, thereby hampering drug discovery. Here we report a data-driven classification of MS disease evolution by analyzing a large clinical trial database (approximately 8,000 patients, 118,000 patient visits and more than 35,000 magnetic resonance imaging scans) using probabilistic machine learning. Four dimensions define MS disease states: physical disability, brain damage, relapse and subclinical disease activity. Early/mild/evolving (EME) MS and advanced MS represent two poles of a disease severity spectrum. Patients with EME MS show limited clinical impairment and minor brain damage. Transitions to advanced MS occur via brain damage accumulation through inflammatory states, with or without accompanying symptoms. Advanced MS is characterized by moderate to high disability levels, radiological disease burden and risk of disease progression independent of relapses, with little probability of returning to earlier MS states. We validated these results in an independent clinical trial database and a real-world cohort, totaling more than 4,000 patients with MS. Our findings support viewing MS as a disease continuum. We propose a streamlined disease classification to offer a unifying understanding of the disease, improve patient management and enhance drug discovery efficiency and precision.
引用
- Ganjgahi H, Häring DA, Aarden P, et al. AI-driven reclassification of multiple sclerosis progression. Nat Med. 2025. PMID: 40835969. doi:10.1038/s41591-025-03901-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。